Graft versus host disease · 13 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cyclosporine, Mycophenolate mofetil, Sirolimus Variant #01 | — | R 124 882 | — | — | — | — | — | — |
Cyclosporine and Mycophenolate mofetil Variant #01 | — | R 83 284 | — | — | — | — | — | — |
Cyclosporine, Methotrexate, Methylprednisolone Variant #01 | — | R 73 709 | — | — | — | — | — | — |
Sitagliptin, Sirolimus, Tacrolimus Variant #01 | — | R 60 269 | — | — | — | — | — | — |
ATG (Rabbit) monotherapy Variant #01 | — | R 44 505 | 18d | — | — | — | — | — |
Cyclosporine, Methotrexate, ATG Variant #01 | — | R 20 027 | — | — | — | — | — | — |
Cyclophosphamide and Cyclosporine Variant #01 | — | R 14 116 | 70d | — | — | — | — | — |
Methotrexate, Tacrolimus, Tocilizumab Variant #01 | — | R 9 718 | — | — | — | — | — | — |
Methotrexate, Tacrolimus, Vorinostat Variant #01 Partial | — | R 5 503 | — | — | — | — | — | — |
Cyclosporine and Methotrexate Variant #01 | — | R 201 | — | — | — | — | — | — |
Methotrexate and Tacrolimus Variant #01 | — | R 2 | — | — | — | — | — | — |
Cyclosporine, Methotrexate, Prednisone Variant #01 Partial | — | — | — | — | — | — | — | — |
Cyclophosphamide, Mycophenolate mofetil, Tacrolimus Variant #01 Partial | — | — | — | — | — | — | — | — |
13 of 13 regimens shown